Trial reportAesthetic surgery journal2026
Effectiveness and Safety of a Polyvinyl Alcohol Microsphere and Hyaluronic Acid Suspension for Chin Augmentation: A Randomized Controlled Trial and Multidisciplinary Study.
Trial report in Aesthetic surgery journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regenerative Functional Microspheres for Aesthetic Medicine: Mechanism, Materials, Fabrication, and Clinical Applications.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDermal fillers are a primary treatment for chin retrusion. However, current options have limitations in longevity and biomechanical properties.
objectivesThe aim of this study was to evaluate the efficacy and safety of a novel filler, comprised of polyvinyl alcohol (PVA) microspheres suspended in hyaluronic acid (PVA-HA), for chin augmentation.
methodsThe physicochemical properties of PVA were compared to those of traditional filler materials by measuring the contact angle, Young's modulus, and friction wear, and by scanning electron microscopy analysis. Biocompatibility was assessed in animal models via histopathological and immunofluorescence analyses. Subsequently, a prospective, randomized controlled trial was conducted from June 2021 to March 2023 in 144 subjects with chin retrusion, randomly allocated 3:1 to receive PVA-HA or no treatment. Efficacy was assessed by changes in the glabella-subnasale-pogonion (G-Sn-Pog') angle, a chin retrusion scale, and the Global Aesthetic Improvement Scale.
resultsPreclinical tests demonstrated that PVA microspheres had favorable hydrophilicity, softness, and mechanical properties, comparable to natural periosteum. In animal models, PVA-HA exhibited excellent biocompatibility with only a mild, transient inflammatory response. In the clinical trial, the PVA-HA group showed a mean G-Sn-Pog' angle increase of 1.12° (95% CI, 0.83°-1.41°) at 60 weeks, compared with a mean decrease of 0.42° (95% CI, -0.87° to 0.03°) in the control group (between-group difference, 1.54°; P < .01). Significant improvements were also observed on both the Global Aesthetic Improvement Scale and the chin retrusion scale (both P < .001). Adverse events were primarily mild-to-moderate, transient injection-site responses.
conclusionsThe novel PVA-HA filler demonstrates favorable physicochemical and biocompatibility properties. It provides clinically significant and safe outcomes in chin augmentation, representing a promising new option for soft tissue filling. LEVEL OF EVIDENCE: 2 (THERAPEUTIC):
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.